Skip to main content
Equibles
CNMD logo

CNMD · CONMED Corp · Documents

Track CNMD — free

Use CNMD with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CNMD.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$50.59 +0.11 (+0.22%) At close · Nov 13 Play latest call Q2 2026 earnings call transcript
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$1.51B
Shares
29.80M
Volume · Nov 13 189.73K Avg daily vol (3M) 361.46K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $1.37B up 5.2% 10-K filed Feb 17, 2026 Quarterly report FY2026 Q3 Revenue $335.56M down 0.7% 10-Q filed Oct 28, 2026 Latest results Financial results 8-K filed Oct 28, 2026 Earnings call Q2 2026 earnings call Held Jul 29, 2026
2026
Oct 28
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Quarterly report for FY2026 Q3

CONMED reported results for the nine months ended September 30, 2026: net sales of $996.1 million, down 0.5%, and net income of $56.7 million; gross margin rose to 57.2%. Operating cash flow was $100.0 million.

Revenue $335.56M ▼ 0.7% Net income $19.8M ▲ 592.4% Diluted EPS $0.66 ▲ 633.3%
Read from the MD&A section
Oct 28
Current report 8-K
Financial results

CONMED Corporation posted third-quarter sales of $335.6 million, down 0.7% year-over-year, and organic constant-currency growth of 6.7%. Diluted EPS was $0.66 and adjusted diluted EPS was $1.04; full-year sales guidance is $1,360 million–$1,366 million and adjusted diluted EPS is $4.54–$4.61.

Jul 29
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $343.49M ▲ 0.3% Net income $23.07M ▲ 7.7% Diluted EPS $0.77 ▲ 11.6%
Apr 30
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $317.05M ▼ 1.3% Net income $13.83M ▲ 129.1% Diluted EPS $0.45 ▲ 136.8%
Apr 7
Proxy statement DEF 14A Meeting May 18, 2026
Proxy statement AI summary on its way
Feb 17
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $1.37B ▲ 5.2% Net income $47.06M ▼ 64.5% Diluted EPS $1.51 ▼ 64.5%
2025
Nov 6
Quarterly report 10-Q FY2025 Q3, ended Sep 30
Quarterly report for FY2025 Q3
Revenue $337.93M ▲ 6.7% Net income $2.86M ▼ 94.2% Diluted EPS $0.09 ▼ 94.3%
Jul 31
Quarterly report 10-Q FY2025 Q2, ended Jun 30
Quarterly report for FY2025 Q2
Revenue $342.35M ▲ 3.1% Net income $21.42M ▼ 28.5% Diluted EPS $0.69 ▼ 28.1%
May 1
Quarterly report 10-Q FY2025 Q1, ended Mar 31
Quarterly report for FY2025 Q1
Revenue $321.26M ▲ 2.9% Net income $6.04M ▼ 69.4% Diluted EPS $0.19 ▼ 69.8%
Feb 18
Annual report 10-K FY2024, ended Dec 31
Annual report for FY2024
Revenue $1.31B ▲ 5.0% Net income $132.42M ▲ 105.4% Diluted EPS $4.25 ▲ 108.3%
2024
Oct 31
Quarterly report 10-Q FY2024 Q3, ended Sep 30
Quarterly report for FY2024 Q3
Revenue $316.7M ▲ 4.0% Net income $48.98M ▲ 209.3% Diluted EPS $1.57 ▲ 214.0%
Showing 1–50 of 163 documents
Key facts CIK 816956 CUSIP 207410101 13F (30d) 231 filings 195 filers Visit website Investor relations